This article was downloaded by: [UQ Library] On: 15 June 2015, At: 04:29 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Synthesis and Analgesic Activities of Some 2-(Benzazolylacetyl)amino-3ethoxycarbonylthiophene Derivatives

Seref Demirayak^a, Ahmet C. Karaburun^a, Ismail Kayagil^a, Umit Uçucu^a & Rana Beis^b

^a Anadolu University, Department of Pharmaceutical Chemistry , Eskisehir, Turkey

^b Anadolu University, Department of Pharmaceutical Chemistry, Eskisehir, Turkey Published online: 18 Aug 2006.

To cite this article: Seref Demirayak , Ahmet C. Karaburun , Ismail Kayagil , Umit Uçucu & Rana Beis (2005) Synthesis and Analgesic Activities of Some 2-(Benzazolylacetyl)amino-3-ethoxycarbonylthiophene Derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements, 180:8, 1841-1848, DOI: <u>10.1080/104265090889503</u>

To link to this article: http://dx.doi.org/10.1080/104265090889503

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and

are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions



Synthesis and Analgesic Activities of Some 2-(Benzazolylacetyl)amino-3-ethoxycarbonylthiophene Derivatives

Seref Demirayak Ahmet C. Karaburun Ismail Kayagil Umit Uçucu Anadolu University, Department of Pharmaceutical Chemistry, Eskisehir, Turkey

Rana Beis

Anadolu University, Department of Pharmacology, Eskisehir, Turkey

In this study, some 2-[2-(benzazole-2-thioxy)acetylamino]-3-ethoxycarbonylthiophene and 2-[2-(benzazole-1-yl)acetylamino]-3-ethoxycarbonylthiophene compounds were obtained by the reaction of 2-chloroacetylamino-3-ethoxycarbonylthiophene derivatives and a suitable benzazole-2-thione or benzimidazole derivatives. Analgesic activities of the compounds were tested by using tail-flick and tail-immersion methods. It is reported that some of the compounds showed remarkable analgesic activities.

Keywords Analgesic activity; benzazole; thiophene

INTRODUCTION

The role of thiophene derivatives in the design and synthesis of pharmacologically important molecules has grown enormously since 1950.^{1,2} The electron-rich properties as well as the slightly smaller steric volume of thiophene, as compared with benzene, may play an important role in fitting the necessary biological agents of this type, which have been prepared based upon active benzene derivatives.

It is well known that, 2-aminothiophenes and their substituted acyl derivatives I show analgesic and anti-inflammatory activities.¹⁻⁸

Received July 8, 2004; accepted September 7, 2004.

Address correspondence to Seref Demirayak, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskisehir, Turkey. E-mail: sdemiray@anadolu.edu.tr



FORMULA 1

It was reported that some of the compounds were superior to some widespread analgesics such as acetylsalicylic acid, phenylbutazone, aminopyrine and indomethacin. In light of the above findings, we aimed to synthesize some 2-(2-benzazolylthio/1-benzimidazolyl-acetyl)amino-3-ethoxycarbonylthiophene derivatives and investigate their analgesic activities.

EXPERIMENTAL

Chemistry

Melting points were determined by using an Electrothermal 9100 digital melting point apparatus and were uncorrected. Spectroscopic data were recorded on the following instruments; FTIR, Schimadzu 8400S spectrophotometer, and ¹H-NMR, Bruker DPX 400 NMR spectrometer in DMSO- d_6 . Analyses for C, H, and N was within 0.4% of the theoretical values.

2-Amino-3-ethoxycarbonylthiophenes, 1,⁹ benzazole-2-thione, 3,¹⁰ and benzimidazole, 5, derivatives¹¹ were prepared according to the literature methods. 2-Chloroacetylamino-3-ethoxycarbonylthiophene derivatives, 2, were obtained by reacting the appropriate 2-amino-3ethoxycarbonylthiophene derivatives with chloroacetyl chloride in the presence of triethylamine in THF, in a common procedure.⁹ Some characteristics of the synthesized compounds were given in Table I.

General Method for the Preparation of 2-[2-(Benzazole-2-thioxy)acetylamino]-3-ethoxycarbonyl-4,5alkylsubstituted thiophene and 2-[2-(Benzazol-1yl)acetylamino]-3-ethoxycarbonyl-4,5-alkylsubstituted thiophene derivatives, 4 and 6

A mixture of **2** (5 mmol), an appropriate **3** or **5** (5 mmol) and potassium carbonate (6 mmol) in acetone (100 mL) was refluxed. In the case

Comp.	R	\mathbf{R}'	$\mathbf{R}^{\prime\prime}$	Х	m.p. ($^{\circ}C$)	Yield (%)	Mol. Formula
4a	-(0	$(H_2)_3 -$	Н	NH	205	72	$C_{19}H_{19}N_3O_3S_2$
4b	-(0	$(H_2)_4 -$	н	NH	159	75	$C_{20}H_{21}N_3O_3S_2$
4c	-(($(H_2)_4 -$	CH_3	NH	164	82	$C_{21}H_{23}N_3O_3S_2$
4d	-(($(H_2)_4 -$	Cl	NH	193	82	$\mathrm{C_{20}H_{20}ClN_3O_3S_2}$
4e	-(($(H_2)_4 -$	NO_2	NH	229	87	$C_{20}H_{20}N_4O_5S_2$
4f	-(($(H_2)_5 -$	н	NH	167	77	$C_{21}H_{23}N_3O_3S_2$
1g	-(0	$(H_2)_4 -$	н	0	113	81	$\mathrm{C}_{20}\mathrm{H}_{22}\mathrm{N}_{2}\mathrm{O}_{4}\mathrm{S}_{2}$
4h	-(($(H_2)_4 -$	CH_3	0	121	73	$\mathrm{C}_{21}\mathrm{H}_{24}\mathrm{N}_{2}\mathrm{O}_{4}\mathrm{S}_{2}$
4i	-(0	$(H_2)_4 -$	Cl	0	129	84	$\mathrm{C}_{20}\mathrm{H}_{21}\mathrm{ClN}_{2}\mathrm{O}_{4}\mathrm{S}_{2}$
4j	-(0	$(H_2)_4 -$	н	\mathbf{S}	140	75	$C_{20}H_{22}N_2O_3S_3$
6a	-(($(H_2)_4 -$	Η	_	176	65	$\mathrm{C}_{20}\mathrm{H}_{21}\mathrm{N}_{3}\mathrm{O}_{3}\mathrm{S}$
6b	-(0	$(H_2)_4 -$	Cl	_	173	67	$\mathrm{C_{20}H_{20}ClN_3O_3S}$

TABLE I Some Characteristics of the Compounds

of the compounds 4, the reflux time is 2 h and in the case of the compounds 6, the reflux time is 12 h. The solvent was evaporated at low temperature. The residue was washed with water and then ethanol. The raw product was recrystallized from ethanol.

4a IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=C). ¹H-NMR(400 MHz)(DMSO-d₆) δ (ppm): 1.25(3H, t, J: 7.08 Hz OCH₂<u>CH₃</u>), 2.26–2.31(2H, m, -CH₂-), 2.75–2.80(4H, m, two -CH₂-), 4.23(2H, q, J: 7.01 Hz, O<u>CH₂CH₃</u>), 4.32(2H, s, CO–CH₂–S), 7.11–7.14(2H, m, Benzimidazole-C_{5.6}–H), 7.45–7.50(2H, m, Benzimidazole-C_{4,7}–H), 11.70(1H, bs, N–H), 12.70(1H, bs, N–H).

4b IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.35(3H, t, J: 8.1 Hz OCH₂<u>CH₃</u>), 1.7–1.85(4H, m, Tetrahydrobenzothiophene-C_{5.6}–H), 2.6–2.7(2H, m, Tetrahydrobenzothiophene-C₇–H), 2.8–2.88(2H, m, Tetrahydrobenzothiophene-C₄–H), 4.24(2H, q, J: 7.08 Hz, O<u>CH₂</u>CH₃), 4.31(2H, s, CO–CH₂–S), 7.2–7.3(2H, m, Benzimidazole-C_{5.6}–H), 7.4–7.48(1H, m, Benzimidazole-C₇–H), 7.65–7.7(1H, m, Benzimidazole-C₄–H), 11.70(1H, bs, N–H), 12.70(1H, bs, N–H).

4f IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=C). ¹H-NMR(400 MHz)(DMSO-d₆) δ (ppm): 1.25(3H, t, J: 7.08 Hz, OCH₂<u>CH₃</u>), 1.48–1.6(4H m, two –CH₂–), 1.74–1.82(2H, m, –CH₂–), 2.57–2.7(2H, m, –CH₂–), 2.9–2.95(2H, m, –CH₂–), 4.25(2H, q, J: 7.1 Hz, O<u>CH₂</u>CH₃), 4.29(2H, s, CO–CH₂–S), 7.10–7.14(2H, m, Benzimidazole-C_{5.6}–H), 7.45–7.50(2H, m, Benzimidazole-C_{4,7}–H), 11.70(1H, bs, N–H), 12.80(1H, bs, N–H).

4g IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.26 (3H, t, J: 7.07 Hz OCH₂<u>CH₃</u>), 1.65–1.75(4H, m, Tetrahydrobenzothiophene-C_{5.6}–H),

2.55–2.60(2H, m, Tetrahydrobenzothiophene- C_7 –H), 2.65–2.70(2H, m, Tetrahydrobenzothiophene- C_4 –H), 4.24(2H, q, J: 7.1 Hz, O<u>CH</u>₂CH₃), 4.31(2H, s, CO–CH₂–S), 7.31–7.36(2H, m, Benzoxazole- $C_{5.6}$ –H), 7.63–7.76(1H, m, Benzoxazole- $C_{4,7}$ –H), 11.68(1H, bs, N–H).

4h IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.27 (3H, t, J: 7.09 Hz OCH₂<u>CH₃</u>), 1.68–1.76(4H, m, Tetrahydrobenzothiophene-C_{5.6}–H), 2.55–2.60(2H, m, Tetrahydrobenzothiophene-C₄–H), 2.65–2.70(2H, m, Tetrahydrobenzothiophene-C₄–H), 4.25(2H, q, J: 7.11 Hz, O<u>CH₂</u>CH₃), 4.42(2H, s, CO–CH₂–S), 7.14(1H, dd, J: 2.85 Hz, J: 8.35 Hz, Benzoxazole-C₆–H), 7.44 (1H, d, J: 0.66 Hz, Benzoxazole-C₄–H), 7.52(1H, d, J: 8.33 Hz, Benzoxazole-C₇–H), 11.67(1H, bs, N–H). **4j** IR(KBr) ν_{max} (cm⁻¹): 3170(N–H), 1664(C=O), 1561–1477(C=N, C=O). ¹H NMP(400 MHz) (DMSO d) δ

C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.27 (3H, t, J: 7.09 Hz OCH₂<u>CH₃</u>), 1.6–1.75(4H, m, Tetrahydrobenzothiophene-C_{5,6}-H), 2.55–2.65(2H, m, Tetrahydrobenzothiophene-C₇-H), 2.65–2.75(2H, m, Tetrahydrobenzothiophene-C₄-H), 4.26(2H, q, J: 7.1 Hz, O<u>CH₂CH₃</u>), 4.46(2H, s, CO-CH₂-S), 7.35–7.39(1H, m, Benzothiazole-C₅-H), 7.45–7.49(1H, m, Benzothiazole-C₆-H), 7.88(1H, d, J: 8.0 Hz, Benzothiazole-C₇-H), 8.03(1H, d, J: 8.01 Hz, Benzothiazole-C₄-H), 11.71(1H, bs, N-H).

6a IR(KBr) ν_{max} (cm⁻¹): 3238(N–H), 1664(C=O), 1535–1494(C=N, C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.27(3H, t, J: 7.1 Hz OCH₂<u>CH₃</u>), 1.7–1.82(2H, m, Tetrahydrobenzothiophene-C_{5,6}–H), 2.6–2.65(2H, m, Tetrahydrobenzothiophene-C₇–H), 2.68–2.75(2H, m, Tetrahydrobenzothiophene-C₄–H), 4.16(2H, q, J: 7.08 Hz, O<u>CH₂</u>CH₃), 5.03(2H, s, CO–CH₂-S), 7.22–7.3(2H, m, Benzimidazole-C_{5,6}–H), 7.38–7.4(1H, m, Benzimidazole-C₇–H), 7.7–7.85(1H, m, Benzimidazole-C₄–H), 8.04(1H, s, Benzimidazole-C₂–H), 11.42(1H, s, NH).

6b IR(KBr) ν_{max} (cm⁻¹): 3238(N–H), 1664(C=O), 1535–1494(C=N, C=C). ¹H-NMR(400 MHz) (DMSO-d₆) δ (ppm): 1.27–1.32(3H, m, OCH₂<u>CH₃</u>), 1.68–1.8 (2H, m, Tetrahydrobenzothiophene-C_{5,6}–H), 2.55–2.6 (2H, m, Tetrahydrobenzothiophene-C₇–H), 2.62–2.75 (2H, m, Tetrahydrobenzothiophene-C₄–H), 4.21–4.28(2H, m, O<u>CH₂</u>CH₃), 5.49, 5.50(2H, two s, CO–CH₂–S), 7.24–7.32(1H, m, Benzimidazole-C₄–H), 7.61–7.80(2H, m, Benzimidazole-C_{7,8}–H), 8.31, 8.34(1H, two s, Benzimidazole-C₂–H), 11.20, 11.21(1H, two s, NH).

Pharmacology

Swiss albino mice of either sex were used for *in vivo* tail-clip and tail immersion (52.5° C hot water) analgesic tests.^{12,13} Mice were assigned to groups of five animals each. Morphine sulfate (10 mg/kg) and

Comp.	Dose (mg/kg) (i.p.)	Reaction Time (sec.)	% Analgesia Tail-Clip
A	10	14.37 ± 0.62	95.38
В	100	14.34 ± 0.66	95.15
4a	100	$13.15 \pm 0.7^{**}$	86.01
4b	100	6.98 ± 2.05	38.00
4c	100	1.30 ± 0.19	0.11
4d	100	11.52 ± 1.56	74.49
4e	100	$12.62 \pm 0.56^{*}$	82.86
4f	100	$11.70 \pm 0.66^{**}$	76.40
4g	100	4.21 ± 2.71	24.50
4h	100	$12.84 \pm 0.15^{*}$	84.40
4i	100	4.29 ± 0.86	19.83
4j	100	$11.68 \pm 0.42^{*}$	74.77
6a	100	1.54 ± 0.29	1.07
6b	100	25 ± 0.07	1.51

TABLE II Effects of the Compounds on Tail-Clip Response in Mice. A: Morphine sulfate, B: Acetylsalisylic Acid. Values are Expressed as Mean \pm S.E.M. of Five Mice in Each Group (*p \leq 0.01 and **p \leq 0.05)

acetylsalisylic acid (100 mg/kg) were used as the reference analgesic agent. Test latencies (in seconds) were assessed 30 min after the administration of compounds. To avoid irreversible damage in tail structures of mice, a maximum latency of 15 s. was imposed, if no response was observed within that time. Percent analgesia was calculated by following formula (% analgesia = {(postdrug latency)-(predrug latency)/(cutoff time)-(predrug latency)} × 100). Results expressed as mean SEM, and student's *t*-test was used to assess statistical significances. Test results are given in Tables II and III.

RESULTS AND DISCUSSION

Chemistry

The synthesis of the title 2-[2-(Benzazole-2-thioxy)acetylamino]-3-ethoxycarbonylthiophene and 2-[2-(benzazole-1-yl)acetylamino]-3ethoxycarbonylthiophene derivatives, **4** and **6**, were accomplished in accordance with the sequence of reactions depicted in Scheme 1. The starting compounds, 2-amino-3-ethoxycarbonyl-4,5-alkylsubstituted thiophenes **1**, were prepared according to Gewald's Method⁶ by the reaction of an appropriate cycloalkanone and ethyl cyanoacetate in the presence of sulphur and morpholine as a base catalyst in ethanol. 2-Chloroacetylamino-3-ethoxycarbonylthiophene



SCHEME 1 (a) EtOH/Morpholine, (b) Et₃N/THF, and (c) K₂CO₃/Acetone.

derivatives **2** were obtained by reacting the appropriate 2-amino-3ethoxycarbonylthiophene derivatives with chloroacetyl chloride in the presence of triethylamine in THF in a common procedure.⁹ The resulting compounds **4** and **6** were prepared by reacting an appropriate **2** and a benzazole-2-thione **3** or a benzimidazole **5** in the presence of potassium carbonate in acetone.

The structures of the obtained compounds were elucidated by using the spectral data. In the IR spectra, the characteristic amid N–H and C=O stretching bands were observed at 3200–3100 and 1665 cm⁻¹, respectively. In the NMR spectra, methylene protons of acetyl residue, which are common in all compounds, were observed at about 4.1– 4.2 ppm in case of the compounds **4** and 5 ppm in case of the compounds **6**. Because of the tautomeric equilibrium from N–H in the ring of benzimidazole, the compound **6b**, which synthesized using 5(6)chlorobenzimidazole as starting material, is a mixture of two structural isomers arising 5- and/or 6-chlorobenzimidazolyl residues. Thus, proton

Comp.	Dose (mg/kg) (i.p.)	Reaction Time (sec.)	% Analgesia Tail-immersion
A	10	10.99 ± 1.84	50.7
В	100	6.19 ± 1.41	21.9
4a	100	3.31 ± 0.71	7.3
4b	100	3.89 ± 0.87	5.8
4c	100	2.34 ± 0.67	0.1
4d	100	3.73 ± 0.29	9.6
4e	100	4.97 ± 0.98	19
4f	100	2.79 ± 0.74	6.2
4g	100	5.39 ± 2	3
4 h	100	2.54 ± 0.38	6.73
4i	100	3.70 ± 0.72	6.9
4j	100	4.08 ± 0.89	3
6a	100	3.28 ± 0.40	2.3
6b	100	5.66 ± 2.12	12.2

TABLE III Effects of the Compounds on
Tail-Immersion Response in Mice. A: Morphine
Sulfate, B: Acetylsalisylic Acid. Values are Expressed
as Mean \pm S.E.M. of Five Mice in Each Group

signals in the NMR spectra were observed as overlaped. The peaks expected singlets were obtained as two singlets. However, the integral values of the peaks, belonging to the similar protons in each isomer, were in accordance. The other protons were obtained as multiplets as expected.

Pharmacology

Analgesic activities of the compounds were tested by using "tail-flick" and "tail-immersion" methods. The analgesic activity in each group is shown in Tables II and III. As control analgesic agents, morphine sulfate (10 mg/kg) and acetylsalisylic acid (100 mg/kg) were used and in tail clip method 95.38% and 95.15% and in tail immersion method 50.7% and 21.9% analgesic activity were observed, respectively.

In tail clip method, among the compounds tested **2a**, **2e**, and **2h** showed remarkable activity in regard to the effects of morphine sulfate and acetylsalisylic acid. The activity obtained is quite close to the activity observed for both morphine sulfate and acetylsalisylic acid. The other notable compounds **2d**, **2f**, and **2j** showed about 75% activity. It is noticeable that the effective compounds are carrying sulfanyl-bridged benzazole residue. However, the compounds **6a** and **6b** which are directly attached to benzimidazole residues do not show any analgesic activity.

The higher activity levels mentioned above were not observed in the tail-immersion experiments. Thus, it could be said that the compounds exhibited potent analgesic activity against physical stimuli, and they were found as potent as acetylsalisylic acid (ip. 100 mg/kg).

REFERENCES

- [1] J. B. Press, Chem. Heterocycl. Compd., 44, 353 (1985).
- [2] J. B. Press, Chem. Heterocycl. Compd., 50, 397 (1991).
- [3] M. Nakanishi, H Imamura, and Y. Maruyama Arzneim.-Forsch., 20, 998 (1970).
- [4] M. Nakanishi, H. Imamura, K. Ikegami, and K. Goto, Arzneim.-Forsch., 20, 1004 (1970).
- [5] M. Perissin, C. L. Duc, G. Narcisse, F. Bakri-Logeais, and F. Huguet, Eur. J. Med. Chem. Chim. Ther., 15, 413 (1980).
- [6] F. Russo, S. Guccione, G. Romeo, G. U. Barretta, S. Pucci, A. Caruso, et al. Eur. J. Med. Chem., 28, 363 (1993).
- [7] F. Russo, G. Romeo, N. A. Santagati, A. Caruso, V. Cutuli, and D. Amore, *Eur. J. Med. Chem.*, **29**, 569 (1994).
- [8] A. Santagati, G. Granata, V. Cutuli, N. G. Mangano, and A. Caruso, Arzneim.-Forsch., 52, 448 (2002).
- [9] K. Gewald, E. Schinke, and H. Bottcher, Chem. Ber., 99, 94 (1966).
- [10] J. A. Van Allan and B. D. Deacon, Org. Synt., 30, 56 (1950).
- [11] M. A. Phillips, J. Chem. Soc., 1143 (1931).
- [12] F. E. D'Amour and D. L. Smith, J. Pharmacol. Exp. Ther., 72, 74 (1941).
- [13] C. Schmauss and T. L. Yaksh, J. Pharmacol. Exp. Ther., 228, 1 (1984).